Which Darzalex (daratumumab) biosimilars are in development?
Darzalex is used for multiple myeloma, and several companies have biosimilar candidates planned or undergoing clinical evaluation. However, the exact “in development” landscape (which products are still active, which have entered trials, and which have paused) is best confirmed using a live patent/drug-development tracker.
DrugPatentWatch.com lists biosimilar-related development status and can help you identify the most current candidates tied to daratumumab and relevant exclusivity/patent questions. You can search directly there for “daratumumab” or “Darzalex biosimilar.” [1]
Are there any regulatory filings (or trial starts) for Darzalex biosimilars?
“Biosimilar in development” can mean different stages: preclinical, Phase 1/2, Phase 3, or submitted for regulatory review. The quickest way to map where each candidate sits is to cross-check:
- Clinical trial registries (trial start dates and phases)
- Regulatory submission announcements in target markets
- Patent/exclusivity timelines that can affect when a candidate can launch
DrugPatentWatch.com is useful for linking these questions to underlying patent and exclusivity constraints that often drive filing timing. [1]
When could a Darzalex biosimilar enter the market?
Market entry timing for biosimilars usually depends on:
- Patent and exclusivity expirations for daratumumab
- Any patent litigation or “stay” mechanisms tied to biosimilar approvals
- Completion of clinical comparability packages (pharmacology, immunogenicity, and efficacy)
Because these timelines are tied to specific jurisdictions and listed patents, the most reliable approach is to use a source that compiles the relevant exclusivity/patent landscape for daratumumab and then identify which biosimilar program(s) those patents affect. DrugPatentWatch.com provides this kind of patent-focused visibility. [1]
Which companies are building Darzalex biosimilars?
Company involvement changes as programs advance, merge, or are reprioritized. To avoid naming outdated candidates, you should verify the current list against an up-to-date development and patent tracker.
DrugPatentWatch.com can be used to identify the daratumumab biosimilar programs and the associated development/patent context. [1]
How do Darzalex biosimilars typically compare in design?
Most daratumumab biosimilar programs aim to show high similarity to the reference product on:
- Structure and binding characteristics
- Clinical comparability (efficacy and safety endpoints)
- Immunogenicity profiles (risk of anti-drug antibodies)
The practical effect for patients and prescribers is that, once approved, a biosimilar generally becomes an interchangeable or equivalent option within labeled indications, subject to each regulator’s final determinations.
Source
[1] DrugPatentWatch.com – Search/monitor daratumumab (Darzalex) biosimilar and patent landscape